This paper is in the following e-collection/theme issue:

Corrigenda and Addenda (111)

Published on in Vol 26 (2024)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/67994, first published .
Correction: Feasibility, Preference, and Impact of a Rapid Multiplexed Point-of-Care Digital Innovation (AideSmart!) to Expedite Screening of Sexually Transmitted Blood-Borne Infections in At-Risk Populations in Canada: Cross-Sectional Study

Correction: Feasibility, Preference, and Impact of a Rapid Multiplexed Point-of-Care Digital Innovation (AideSmart!) to Expedite Screening of Sexually Transmitted Blood-Borne Infections in At-Risk Populations in Canada: Cross-Sectional Study

Correction: Feasibility, Preference, and Impact of a Rapid Multiplexed Point-of-Care Digital Innovation (AideSmart!) to Expedite Screening of Sexually Transmitted Blood-Borne Infections in At-Risk Populations in Canada: Cross-Sectional Study

Authors of this article:

Angela Karellis1 Author Orcid Image ;   Duncan Webster2 Author Orcid Image ;   Jean Boulanger3 Author Orcid Image ;   Kate Harland2 Author Orcid Image ;   Paige Feltmate2 Author Orcid Image ;   Stefanie Materniak2 Author Orcid Image ;   Gabriel Daunais-Laurin3 Author Orcid Image ;   Christine Mesa4 Author Orcid Image ;   Olivia Vaikla1 Author Orcid Image ;   John Kim4 Author Orcid Image ;   Nitika Pant Pai1, 5 Author Orcid Image
Article Authors Cited by Tweetations Metrics

    Original Paper

    1Infectious Diseases and Immunity in Global Health, Research Institute of the McGill University Health Centre, Montreal, QC, Canada

    2Centre for Research, Education & Clinical Care of At-Risk Populations, Saint John, NB, Canada

    3REZO, Montreal, QC, Canada

    4National Laboratory for HIV Reference Services, Public Health Agency of Canada, Winnipeg, MB, Canada

    5Faculty of Medicine, McGill University, Montreal, QC, Canada

    Corresponding Author:

    Nitika Pant Pai, MPH, MD, PhD

    Infectious Diseases and Immunity in Global Health

    Research Institute of the McGill University Health Centre

    5252 boul de Maisonneuve Ouest

    Montreal, QC, H4A3S5

    Canada

    Phone: 1 514 934 1934 ext 44729

    Email: nitika.pai@mcgill.ca



    In “Feasibility, Preference, and Impact of a Rapid Multiplexed Point-of-Care Digital Innovation (AideSmart!) to Expedite Screening of Sexually Transmitted Blood-Borne Infections in At-Risk Populations in Canada: Cross-Sectional Study” (J Med Internet Res 2024;26:e55075), 2 errors were made during the publication process.

    1) Affiliations 1 and 4:

    1. Research Institute of the McGill University Health Centre, Montreal, QC, Canada
    4. National Laboratory for HIV Reference Services, Winnipeg, MB, Canada

    Have been revised to include subunits, as follows:

    1. Infectious Diseases and Immunity in Global Health, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
    4. National Laboratory for HIV Reference Services, Public Health Agency of Canada, Winnipeg, MB, Canada

    2) Tables 3 and 4 have been revised to adjust some numbers in “Sensitivity” and “Specificity” columns, as follows:

    Table 3. Diagnostic accuracy of the Chembio and MedMira point-of-care (POC) tests in comparison to local laboratory tests in the AideSmart! cross-sectional multiplexed rapid sexually transmitted blood-borne infection screening study in Canada (2021-2022).
    POC testSensitivity, % (95% CI)Specificity, % (95% CI)
    HIV

    		Chembio100.00 (79.41-100.00)98.71 (96.72-99.65)

    		MedMira100.00 (78.20-100.00)100.00 (98.82-100.00)
    Syphilis

    		Chembio86.84 (71.91-95.59)99.65 (98.06-99.99)

    		MedMira57.89 (40.82-73.69)100.00 (98.72-100.00)
    Hepatitis C

    		Chembio—a—

    		MedMira90.32 (80.12-96.37)99.62 (97.92-99.99)

    aNot applicable.

    Table 4. Diagnostic accuracy of the Chembio and MedMira point-of-care (POC) tests in comparison to dried blood spot tests in the AideSmart! cross-sectional multiplexed rapid sexually transmitted blood-borne infection screening study in Canada (2021-2022).
    POC testSensitivity, % (95% CI)Specificity, % (95% CI)
    HIV

    		Chembio100.00 (76.84-100.00) 98.94 (97.30-99.71) 

    		MedMira93.75 (69.77-99.84) 100.00 (99.02-100.00) 
    Syphilis

    		Chembio80.00 (64.35-90.95)99.03 (97.19-99.80)

    		MedMira55.00 (38.49-70.74) 100.00 (98.81-100.00) 
    Hepatitis C

    		Chembio—a—

    		MedMira91.15 (84.33-95.67)99.29 (97.46-99.91)

    aNot applicable.

    The correction will appear in the online version of the paper on the JMIR Publications website on October 28, 2024 together with the publication of this correction notice. Because this was made after submission to PubMed and other full-text repositories, the corrected article has also been resubmitted to those repositories.

    This is a non–peer-reviewed article. submitted 25.10.24; accepted 25.10.24; published 28.10.24.

    Copyright

    ©Angela Karellis, Duncan Webster, Jean Boulanger, Kate Harland, Paige Feltmate, Stefanie Materniak, Gabriel Daunais-Laurin, Christine Mesa, Olivia Vaikla, John Kim, Nitika Pant Pai. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 28.10.2024.

    This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in the Journal of Medical Internet Research (ISSN 1438-8871), is properly cited. The complete bibliographic information, a link to the original publication on https://www.jmir.org/, as well as this copyright and license information must be included.